Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation

Future Oncology

Volumn 11, Issue 1, 2015, Pages 61-71

  Jackisch, Christian ^a   Scappaticci, Frank A ^b   Heinzmann, Dominik ^c   Bisordi, Fabio ^c   Schreitmüller, Thomas ^c   Minckwitz, Gunter Von ^a   Cortés, Javier ^d  

^a Department of Obstetrics and Gynecology Breast Cancer Center Gynecologic Cancer Center ^*  (Germany)

^b GENENTECH INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Biosimilar; breast cancer; HER2; Herceptin ^{< sup>; meta analysis; metastatic breast cancer; neoadjuvant; trastuzumab}

Indexed keywords

DRUG ANTIBODY; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DRUG EFFICACY; EARLY CANCER; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; META ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 84921058776     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.187     Document Type: Article

References (36)

1. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 (2003).
2. US FDA prescribing information for Herceptin®. www.accessdata.fda.gov/drugsatfda-docs/label/2010/103792s5250lbl.pdf
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
4. EMA Summary of product characteristics for Herceptin. www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000278/WC500074922. pdf
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
7. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2011).
8. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
9. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375, 377-384 (2010).
10. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. doi:10.1016/S1470-2045(14)70080-4 (2014) (Epub ahead of print).
11. Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 13, 869-878 (2012).
12. Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J. Natl Compr. Canc. Netw. 9, 934-942 (2011).
13. Jelkmann W. Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences. Am. J. Hematol. 85, 771-780 (2010).
14. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues (2012).
15. Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67, 2346-2353 (2005).
16. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20(Suppl. 6), vi3-vi9 (2005).
17. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol. Dial. Transplant. 21(Suppl. 5), v4-v8 (2006).
18. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann. Oncol. 19, 411-419 (2008).
19. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012).
20. US Food and Drug Administration. Guidance for Industry: Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an end point to Support Accelerated Approval (2012).
21. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet doi: 10.1016/S0140-6736(13)62422-8 (2014) (Epub ahead of print).
22. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796-1804 (2012).
23. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol. 26, 1987-1992 (2008).
24. Cook JR, Stefanski LA. Simulation-extrapolation estimation in parametric measurement error models. J. Am. Stat. Assoc. 89, 1314-1328 (1994).
25. Hegg R, Pienkowski T, Chen S-T et al. Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the Phase III HannaH study. Poster presentation 232P, ESMO, Vienna, Austria, 28 September-2 October 2012.
26. Gianni L, Romieu GH, Lichinitser M et al. AVEREL: a randomized Phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol. 31, 1719-1725 (2013).
27. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119 (2012).
28. Valero V, Forbes J, Pegram MD et al. Multicenter Phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J. Clin. Oncol. 29, 149-156 (2011).
29. Wardley AM, Pivot X, Morales-Vasquez F et al. Randomized Phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 976-983 (2010).
30. Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157-1163 (2013).
31. Robert N, Leyland-Jones B, Asmar L et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 24, 2786-2792 (2006).
32. Baselga J, Manikhas A, Cortés J et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann. Oncol. 25, 592-598 (2014).
33. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Geparquattro study. J. Clin. Oncol. 28, 2024-2031 (2010).
34. von Minckwitz G, Rezai M, Fasching PA et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40 GeparQuattro). Ann. Oncol. 25, 81-89 (2014).
35. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21, 211-215 (2009).
36. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 14, 296-302 (2012).